<DOC>
	<DOCNO>NCT02149121</DOCNO>
	<brief_summary>This Phase 3 Study Compare Pharmacokinetics , Efficacy Safety CT-P10 , Rituxan MabThera Patients Rheumatoid Arthritis .</brief_summary>
	<brief_title>PK Similarity Prospective Phase 3 Study Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patient male female 18 75 year old , inclusive . 2 . Patient diagnosis RA accord revised 1987 ACR classification criterion ( Arnett et al 1988 ) least 6 month prior randomization . 3 . Patient active disease define presence 6 swollen joint ( 66 assess ) 6 tender joint ( 68 assess ) , serum CRP ≥1.5 mg/dL ( ≥15 mg/L ) ESR ≥28 mm/hour . 4 . Patient experience inadequate response previous current treatment antiTNF agent infliximab 5 . Patient proper discontinuation period treatment interleukin1 receptor ( IL1R ) antagonist , interleukin6 receptor ( IL6R ) antibody , abatacept . 1 . Patient take 2 biologic agent . 2 . Patient previously administer Rituximab participate Rituximab biosimilar study . 3 . Patient allergy hypersensitivity murine , chimeric , human , humanized protein . 4 . Patient current past history chronic infection hepatitis B , hepatitis C , infection human immunodeficiency virus ( HIV ) 1 2 positive result screen test infection . 5 . Patient infection require oral antibiotic 2 week randomization , parenteral injection antibiotic 4 week randomization , serious infection 6 month randomization , history recurrent herpes zoster chronic recurrent infection 6 week randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>